Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Acquisitions & Divestments (2016 - 2022)

Catalyst Pharmaceuticals filings provide 8 years of Change in Acquisitions & Divestments readings, the most recent being $9.9 million for Q3 2022.

  • On a quarterly basis, Change in Acquisitions & Divestments changed N/A to $9.9 million in Q3 2022 year-over-year; TTM through Dec 2022 was $9.9 million, a N/A change, with the full-year FY2022 number at $19.2 million, changed N/A from a year prior.
  • Change in Acquisitions & Divestments hit $9.9 million in Q3 2022 for Catalyst Pharmaceuticals, up from $5.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $31.7 million in Q4 2019 to a low of $5.0 million in Q1 2020.
  • Median Change in Acquisitions & Divestments over the past 4 years was $10.0 million (2019), compared with a mean of $14.4 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: soared 122.95% in 2019 and later plummeted 75.49% in 2020.
  • Catalyst Pharmaceuticals' Change in Acquisitions & Divestments stood at $14.2 million in 2018, then soared by 122.95% to $31.7 million in 2019, then crashed by 84.21% to $5.0 million in 2020, then skyrocketed by 97.36% to $9.9 million in 2022.
  • The last three reported values for Change in Acquisitions & Divestments were $9.9 million (Q3 2022), $5.0 million (Q1 2020), and $31.7 million (Q4 2019) per Business Quant data.